New hope for sarcoma patients: immunotherapy plus chemo shows promise
NCT ID NCT06849986
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of drugs (tislelizumab, liposomal doxorubicin, and ifosfamide) as a first treatment for people with advanced soft tissue sarcoma that cannot be removed by surgery or has spread. The goal is to see if this combo shrinks tumors and is safe. About 45 adults aged 18-75 with specific sarcoma types will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor-Injected drug combo outlast standard care in advanced sarcoma?
- Can a Two-Drug combo stop nerve tumors from turning cancerous?
- Could a genetic marker guide future cancer therapies in taiwan?
- Radioactive antibody targets rare childhood cancer
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- New immunotherapy targets genetic flaw in rare childhood cancers